Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.32 |
| ▸ | ADH1A | P07327 | 3/20 | 0.31 |
| ▸ | ADH1C | P00326 | 2/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238560 | 0.98 | ALOX5 (0.39) | ALOX5EPHX1ADH1AADH1CADRA2A | |
| SCHEMBL3711995 | 0.81 | ALDH1A1 (0.35) | ALOX5EPHX1ADRA2A | |
| SCHEMBL3711997 | 0.81 | ALDH1A1 (0.35) | ALOX5EPHX1ADRA2A | |
| SCHEMBL14791027 | 0.77 | LMNA (0.37) | ADH1AADH1CADH4ADRA2APDE4A | |
| SCHEMBL102987 | 0.76 | LMNA (0.36) | ADH1AADH1CADRA2APDE4AADRA1A | |
| SCHEMBL14794984 | 0.74 | — | — | |
| SCHEMBL14776360 | 0.74 | ADH1C (0.35) | ADH1AADH1C | |
| SCHEMBL12506208 | 0.71 | ADRA2A (0.56) | EPHX1ADRA2APDE4AADRA1A | |
| SCHEMBL39462 | 0.71 | ADRA2A (0.40) | EPHX1ADH1AADH1CADRA2APDE4A | |
| SCHEMBL103331 | 0.71 | RAB9A (0.33) | EPHX1ADH1AADH1CADRA2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ALOX5 1447/4885EPHX1 1518/4885ADH1A 3778/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ALOX5 1365/4885EPHX1 1492/4885ADH1A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.